Clinical trial
Alanosine in Treating Patients With Cancer
NCT00062283 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00062283 |
|---|---|
| Title | Alanosine in Treating Patients With Cancer |
| Official title | A Phase II, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Intravenous SDX-102 for the Treatment of Patients With MTAP-Deficient Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Sarcoma |
| Intervention type | Drug |
| Interventions | L-alanosine |
| Start date | Mar 1, 2003 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2009 |
| First posted | Jun 6, 2003 |
| Last update posted | Jun 26, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: